世界の多発性骨髄腫治療薬市場2020年:企業別・地域別・種類別・用途別市場予測(~2025年)

GlobalInfoResearchが発行した調査報告書(GIR20SP12257)
◆英語タイトル:Global Multiple Myeloma Treatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025
◆商品コード:GIR20SP12257
◆発行会社(リサーチ会社):GlobalInfoResearch
◆発行日:2020年9月25日(※2024年版があります。お問い合わせください。)
◆ページ数:108
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療、製薬、バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥515,040見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥772,560見積依頼/購入/質問フォーム
Corporate User(同一法人内共有可)USD6,960 ⇒換算¥1,030,080見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalInfoResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートでは、多発性骨髄腫治療薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。多発性骨髄腫治療薬の種類別市場規模(プロテアソーム阻害剤、免疫調節剤(IMiD)、ヒストンデアセチラーゼ(HDAC)阻害剤、免疫療法、細胞毒性化学療法)、用途別市場規模(病院、クリニック、がん治療・リハビリセンター)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。
・市場概要
・企業情報(販売量、市場シェア、製品概要、SWOT分析):Johnson & Johnson、Eli Lilly、Roche Holding、Sanofi、Novartis
・地域別グローバル市場分析 2015年-2020年
・多発性骨髄腫治療薬の北米市場(アメリカ、カナダ、メキシコ)
・多発性骨髄腫治療薬のヨーロッパ市場(ドイツ、イギリス、フランス、ロシア、イタリア)
・多発性骨髄腫治療薬のアジア市場(中国、日本、韓国、インド、東南アジア、オーストラリア)
・多発性骨髄腫治療薬の南米市場(ブラジル、アルゼンチン)
・多発性骨髄腫治療薬の中東・アフリカ市場(サウジアラビア、トルコ、エジプト、南アフリカ)
・種類別分析:プロテアソーム阻害剤、免疫調節剤(IMiD)、ヒストンデアセチラーゼ(HDAC)阻害剤、免疫療法、細胞毒性化学療法
・用途別分析:病院、クリニック、がん治療・リハビリセンター
・地域別市場規模予測 2021年-2025年
・調査の結果・結論
【レポートの概要】

Market Overview
The global Multiple Myeloma Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 10.2% in the forecast period of 2020 to 2025 and will expected to reach USD 41350 million by 2025, from USD 28060 million in 2019.

The Multiple Myeloma Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Multiple Myeloma Treatment market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Multiple Myeloma Treatment market has been segmented into:
Proteasome Inhibitors
Immunomodulatory Agents (IMiDs)
Histone Deacetylase (HDAC) Inhibitors
Immunotherapy
Cytotoxic Chemotherapy

By Application, Multiple Myeloma Treatment has been segmented into:
Hospitals
Clinics
Cancer Treatment and Rehabilitation Centers

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Multiple Myeloma Treatment market presented in the report. This section sheds light on the sales growth of different regional and country-level Multiple Myeloma Treatment markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Multiple Myeloma Treatment market.

The report offers in-depth assessment of the growth and other aspects of the Multiple Myeloma Treatment market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Multiple Myeloma Treatment Market Share Analysis
Multiple Myeloma Treatment competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Multiple Myeloma Treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Multiple Myeloma Treatment sales, revenue and market share for each player covered in this report.

The major players covered in Multiple Myeloma Treatment are:
Johnson & Johnson
Eli Lilly
Roche Holding
Sanofi
Novartis

【レポートの目次】

Table of Contents

1 Multiple Myeloma Treatment Market Overview
1.1 Product Overview and Scope of Multiple Myeloma Treatment
1.2 Classification of Multiple Myeloma Treatment by Type
1.2.1 Global Multiple Myeloma Treatment Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Multiple Myeloma Treatment Revenue Market Share by Type in 2019
1.2.3 Proteasome Inhibitors
1.2.4 Immunomodulatory Agents (IMiDs)
1.2.5 Histone Deacetylase (HDAC) Inhibitors
1.2.6 Immunotherapy
1.2.7 Cytotoxic Chemotherapy
1.3 Global Multiple Myeloma Treatment Market by Application
1.3.1 Overview: Global Multiple Myeloma Treatment Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Cancer Treatment and Rehabilitation Centers
1.4 Global Multiple Myeloma Treatment Market by Regions
1.4.1 Global Multiple Myeloma Treatment Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Multiple Myeloma Treatment (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Multiple Myeloma Treatment Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Multiple Myeloma Treatment Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Multiple Myeloma Treatment Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Multiple Myeloma Treatment Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Multiple Myeloma Treatment Status and Prospect (2015-2025)
2 Company Profiles
2.1 Johnson & Johnson
2.1.1 Johnson & Johnson Details
2.1.2 Johnson & Johnson Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Johnson & Johnson SWOT Analysis
2.1.4 Johnson & Johnson Product and Services
2.1.5 Johnson & Johnson Multiple Myeloma Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.2 Eli Lilly
2.2.1 Eli Lilly Details
2.2.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Eli Lilly SWOT Analysis
2.2.4 Eli Lilly Product and Services
2.2.5 Eli Lilly Multiple Myeloma Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.3 Roche Holding
2.3.1 Roche Holding Details
2.3.2 Roche Holding Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Roche Holding SWOT Analysis
2.3.4 Roche Holding Product and Services
2.3.5 Roche Holding Multiple Myeloma Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.4 Sanofi
2.4.1 Sanofi Details
2.4.2 Sanofi Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Sanofi SWOT Analysis
2.4.4 Sanofi Product and Services
2.4.5 Sanofi Multiple Myeloma Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.5 Novartis
2.5.1 Novartis Details
2.5.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Novartis SWOT Analysis
2.5.4 Novartis Product and Services
2.5.5 Novartis Multiple Myeloma Treatment Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Multiple Myeloma Treatment Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Multiple Myeloma Treatment Players Market Share
3.2.2 Top 10 Multiple Myeloma Treatment Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Multiple Myeloma Treatment Revenue and Market Share by Regions
4.2 North America Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
4.3 Europe Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
4.5 South America Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
5 North America Multiple Myeloma Treatment Revenue by Countries
5.1 North America Multiple Myeloma Treatment Revenue by Countries (2015-2020)
5.2 USA Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
5.3 Canada Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
5.4 Mexico Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
6 Europe Multiple Myeloma Treatment Revenue by Countries
6.1 Europe Multiple Myeloma Treatment Revenue by Countries (2015-2020)
6.2 Germany Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
6.3 UK Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
6.4 France Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
6.5 Russia Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
6.6 Italy Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Multiple Myeloma Treatment Revenue by Countries
7.1 Asia-Pacific Multiple Myeloma Treatment Revenue by Countries (2015-2020)
7.2 China Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
7.3 Japan Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
7.4 Korea Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
7.5 India Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
8 South America Multiple Myeloma Treatment Revenue by Countries
8.1 South America Multiple Myeloma Treatment Revenue by Countries (2015-2020)
8.2 Brazil Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
8.3 Argentina Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Multiple Myeloma Treatment by Countries
9.1 Middle East & Africa Multiple Myeloma Treatment Revenue by Countries (2015-2020)
9.2 Saudi Arabia Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
9.3 UAE Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
9.4 Egypt Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
9.5 South Africa Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Multiple Myeloma Treatment Revenue and Market Share by Type (2015-2020)
10.2 Global Multiple Myeloma Treatment Market Forecast by Type (2019-2024)
10.3 Proteasome Inhibitors Revenue Growth Rate (2015-2025)
10.4 Immunomodulatory Agents (IMiDs) Revenue Growth Rate (2015-2025)
10.5 Histone Deacetylase (HDAC) Inhibitors Revenue Growth Rate (2015-2025)
10.6 Immunotherapy Revenue Growth Rate (2015-2025)
10.7 Cytotoxic Chemotherapy Revenue Growth Rate (2015-2025)
11 Global Multiple Myeloma Treatment Market Segment by Application
11.1 Global Multiple Myeloma Treatment Revenue Market Share by Application (2015-2020)
11.2 Multiple Myeloma Treatment Market Forecast by Application (2019-2024)
11.3 Hospitals Revenue Growth (2015-2020)
11.4 Clinics Revenue Growth (2015-2020)
11.5 Cancer Treatment and Rehabilitation Centers Revenue Growth (2015-2020)
12 Global Multiple Myeloma Treatment Market Size Forecast (2021-2025)
12.1 Global Multiple Myeloma Treatment Market Size Forecast (2021-2025)
12.2 Global Multiple Myeloma Treatment Market Forecast by Regions (2021-2025)
12.3 North America Multiple Myeloma Treatment Revenue Market Forecast (2021-2025)
12.4 Europe Multiple Myeloma Treatment Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Multiple Myeloma Treatment Revenue Market Forecast (2021-2025)
12.6 South America Multiple Myeloma Treatment Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Multiple Myeloma Treatment Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

...

【掲載企業】

Johnson & Johnson、Eli Lilly、Roche Holding、Sanofi、Novartis

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の多発性骨髄腫治療薬市場2020年:企業別・地域別・種類別・用途別市場予測(~2025年)(Global Multiple Myeloma Treatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025)]についてメールでお問い合わせはこちらでお願いします。